Bluesheet Contents     PDF version

File Description [top]

IMS R&D Focus is a powerful tool to evaluate the progress of R&D pipelines from Discovery phase to Marketed phase. With more than 23,300 drugs in R&D, 9,400 drugs in active development, and 4,800 biotechnology products, the file provides the latest scientific and commercial developments in international pharmaceutical research and development. All aspects of a drug's development are presented in a convenient "all in one" record format. More than 3,000 companies are profiled with respect to their involvement in the development of a drug as well as their relationships as licensor and licensee. Full commercial summaries provide a commercial overview, regulatory progress, licensing and partnering deals, and analysts' sales predictions.

The file corresponds to the electronic publication R&D Focus (Drug Profile records) and incorporates R&D Focus Drug News, the weekly news service that reports on more than 23,000 drugs compiled by editors via interviews at scientific and investor conferences worldwide. These records cover new drugs in research, changes in development phases, and licensing opportunities. File 445 is publicly available; File 955 is available only to subscribers of R&D Focus and R&D Drug News. Images of chemical structures are available for more than 6,000 Drug Profile records.

Tips [top]

Subject Coverage [top]

IMS R&D Focus provides comprehensive reviews and up-to-date news on drugs in development including full synonyms, licensing status, patent summary, development history, commercial potential, scientific and commercial summaries, and abstracts of significant scientific papers. Scientific summaries detail pre-clinical and clincial data and sales profiles of 123 leading therapeutic classes using IMS sales data. Some financial background of the disease area is provided when available.

Sources [top]

IMS R&D Focus is compiled from a comprehensive range of sources. Primary resources include information provided directly from companies involved in research and development, interviews with key executives, and official press releases. Additional information is gathered from IMS Health staff attendance at international medical and clinical symposia, research conferences and meetings; scanning of scientific proceedings; and medical and patent literature. Information is checked and validated prior to inclusion into R&D Focus.

Print Counterparts [top]

• None

Dialog File Data [top]

Related Search Aids [top]

For additional information about Chemical Structure searching available in this file, please see

Document Types Indexed [top]

• Directories
• Newsletters
• Chemical Substances

Geographic Coverage [top]

• International

Geographic Restrictions [top]

• None

Special Features [top]

• ERA Available
• KWIC and HILIGHT Available
• DIALOG Alert Available
• Image Output Available
• MAP Available
• Chemical Structure Searching Enabled

DialIndex/OneSearch Categories [top]

Contact [top]

Terms and Conditions [top]

For Dialog's Redistribution and Archive Policy, enter HELP ERA online. The following terms and conditions also apply.

These databases are copyrighted by IMSworld Publications. No part of these databases may be copied or duplicated in hard copy or machine-readable form without prior written permission of IMSworld Publications.

If data is to be distributed under Dialog's Redistribution policy, distribution is restricted to within the geographic boundaries of the country where the data was first downloaded. Under NO CIRCUMSTANCES may data which has been downloaded, distributed, or copied under this provision be sold or resold to a third party outside the user's company organization.

DRUG PROFILE SAMPLE RECORD [top]

	DIALOG(R)File 445: IMS R&D Focus
	(c) 2007 IMS Health & Affiliates. All rts. reserv.
	02002151   ** Image available **
/NA,NA=	Drug Name:  lansoprazole
/TN,TN=	Brand Name:  TAKEPRON ; OGAST; LANZOR; AGOPTON; PREVACID; LANZO; OPIREN;
	BAMALITE; ZOTON; OGASTRO
JN=,PD=,PY=	R&D Focus - July 08, 2002 (20020708) 2002
Image
	IM displays the graphic structure when DialogLink 5 is used.
	COMPANY INFORMATION:
/CO,CO=	Originator:               Takeda; (Japan); NA; licensor; France, Japan,
/LO,LO=	Germany, Indonesia, Taiwan
/LI,LI=,RL=	Licensee/Licensor:        Abbott; (USA); NA; licensee; Peru, Venezuela,
RG=	Argentina, Brazil, Central America, Colombia,
CC=	Mexico
	Almirall Prodesfarma; (Spain); NA; licensee;
	Spain
IP=	Argentia; (Argentina); Bristol-Myers Squibb;
	licensee; Argentina
	Aventis; (France); NA; licensee; France,
	Netherlands, Belgium, Africa, Middle East
	Boehringer Ingelheim; (Germany); NA; licensee;
	Latin America
	GlaxoSmithKline; (UK); NA; licensee; UK
	(. . .)
/PA,PA=	Patent Assignee:          Takeda
	DRUG INFORMATION:
RN=	CAS Registry Number:      103577-45-3, lansoprazole; 138530-94-6, (R)/(+)
	; 138530-95-7, (S)/(-); 154727-72-7, replaced
	by 103577-45-3
CD=	Laboratory Code:          AG 1749; CG 4801; A 65006
/AC,AC=	Pharmacological Action:   proton pump inhibitor; imidazole
/TC,TC=	Therapeutic Class Code:   A2B2 (Antiulcerants, Acid Pump Inhibitors); J1X
	(Other Antibiotics)
/IN	Clinical Indications:     gastrointestinal ulcer; bacterial infection
CN=	Chemical Name:            2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyrid
	inyl]methyl]sulfinyl ]-1H-benzimidazole
NC=	Nomenclature:             INN
MC=	Molecular Code:           3982200000
	LATEST INFORMATION:
/TX	29   January  2001:  Takeda's  lansoprazole  (TAKEPRON),  a  proton  pump
	inhibitor,  has  been approved in Japan for maintenance therapy of patients
	with recurrent reflux esophagitis.
	CURRENT DEVELOPMENT STATUS:
DP=,SN=	Highest Phase:            Marketed (80)
	Development Phase/
	Country/Indication:       Marketed, Worldwide, gastrointestinal ulcer
	Marketed, USA, bacterial infection
	Marketed, UK, bacterial infection
	Marketed, Italy, bacterial infection
	Marketed, France, bacterial infection
	Marketed, Germany, bacterial infection
	Registered, Japan, bacterial infection
	DEVELOPMENT HISTORY:
/TX	MAR 2002: American Home Products changes name to Wyeth.
	DEC 2000: Registered, Japan (reflux esophagitis).
	OCT 2000: Marketed, USA;UK;Italy;France;Germany (bacterial infection).
	Pre-registation, Japan (bacterial infection).
	DEC 1999: Hoechst Marion Roussel and Rhone-Poulenc Rorer merge to form
	Aventis.
	JUL 1995: Marketed, USA.
	MAY 1995: Registered, USA.
	FEB 1995: Approvable, USA.
	1994: Marketed, Argentina, Brazil, Central America, Chile, Colombia,
	Denmark, Egypt, Indonesia, Mexico, Pakistan, Peru, Spain, Taiwan,
	Venezuela.
	DEC 1994: Approval recommended, USA.
	(. . .)
	JUN 1986: Preclinical, Japan.
	1984: Priority product patent application filed, Japan.
	COMMERCIAL SUMMARY:
/TX	Lansoprazole  is  a  substituted benzimidazole proton pump inhibitor with
	potent   and  long-lasting  antisecretory  activity  developed  by  Takeda.
	Lansoprazole  was  launched  by  Hoechst  Marion  Roussel  (now Aventis) in
	France,  its  first  world  market,  in  December  1991.  It has since been
	(. . .)
	SCIENTIFIC SUMMARY:
/TX	The  antisecretory  activity  of  lansoprazole  has  been demonstrated in
	isolated  parietal  cells  and  in  dogs and rats. Growth inhibition of the
	urogenital   pathogen  Ureaplasma  urealyticum  by  lansoprazole  has  been
	(. . .)
	PATENT SUMMARY:
/TX	Product:  EP  174726  B  1989,  priority  JP  171069 1984, designating 11
	states.  Equivalents  identified  in 22 countries. Composition: EP 382489 B
	1994, priority JP 32374 1989, designating 14 states. Equivalents identified
	in five countries.

DRUG NEWS SAMPLE RECORD

BASIC INDEX [top]

¹ Includes Company Name of Licensor/Orginator, Licensee/Licensor, and Patent Assignee.

² Searchable in the Basic Index and in the Additional Indexes.

³ Includes Drug Name, Therapeutic Class Code and Description, Company Name, Event Code, New Drug, and New Phase Indicator.

⁴ Available in R&D Focus Drug News records only.

⁵ Display includes Licensee/Licensor, Licensee/Licensor Country, Parent Company of Licensee/Licensor, Company Relationship, and Region of Originator.

⁶ Includes Originator.

⁷ Includes Company Name of Originator, Originator Country, Parent Company of Originator, Company Relationship, and Region of Originator.

⁸ Includes Drug Name, Brand Name, and Laboratory Code.

⁹ Special suffixes are used to further restrict the appropriate prefixed fields as noted: /LI (Licensee), /LO (Licensor).

¹⁰ Available in Drug Profile records only.

¹¹ SORTs for CO and NA work only in Drug Profile records.

ADDITIONAL INDEXES [top]

¹² MC represents a molecular code for each drug entry in all IMS databases.

¹³ Also searchable as /DE.

¹⁴ The graphic structure can be displayed and edited using DialogLink 5.

LIMIT [top]

SORT [top]

RANK [top]

MAP [top]

USER-DEFINED FORMAT OPTIONS [top]

PREDEFINED FORMAT OPTIONS [top]

DIRECT RECORD ACCESS [top]

Rates [top]

Rates For File: IMS R&D Focus[445]
Cost per DialUnit:                $21.00
Cost per minute:                   $3.92
Rank Elements                      $0.00
ALERT (default)                    $8.75
ALERT (Monthly)                *  $21.00
ALERT (Biweekly/twice a month) *  $13.75
ALERT (Weekly)                     $8.75
ALERT (Daily)                  *   $8.75
ALERT (Calendar weekly)        *   $8.75
ALERT (Intraday)               *   $8.75
* = custom scheduled Alerts only
ALERT Number of included prints        0

Format    Types   Prints
     1    $0.00    $0.00
     2   $40.00   $40.00
     3   $40.00   $40.00
     4    $9.00    $9.00
     5   $60.00   $60.00
     6    $0.00    $0.00
     7   $57.00   $57.00
     8    $0.00    $0.00
     9   $60.00   $60.00
    12   $42.00   $42.00
    18    $3.50    $3.50
    19   $66.00   $66.00
KWIC95    $9.00       NA
KWIC96   $60.00       NA

REDIST/COPY Multiplier Table:

      Range      Multiplier
        1-2       1.00
       3-25       1.50
     26-100       3.00
    101-200       4.00
    201-500       6.00
   501-1000       8.00
 1001 or more    10.00

ARCHIVE Multiplier Table:

      Range      Multiplier
       1-25       1.50
     26-200       3.00
    201-500       6.00
   501-1000       8.00
 1001 or more    10.00
---------------------------------

A charge of $20.00 applies to each CSS (Chemical Structure Search)
whether searching in one database or across multiple databases.  The
standard output charges for each database apply to any documents
retrieved.

Rates For File: IMS R&D Focus - subscribers[955]
Cost per DialUnit:                $21.00
Cost per minute:                   $3.92
Report Elements                    $0.00
LOB Reports                        $0.00
SHARE Reports                      $0.00
CROSSTAB Report Records            $0.00
Rank Elements                      $0.00
ALERT (default)                   $21.00
ALERT (Monthly)                *  $23.00
ALERT (Biweekly/twice a month) *  $21.00
ALERT (Weekly)                    $21.00
ALERT (Daily)                  *   $8.75
ALERT (Calendar weekly)        *  $21.00
ALERT (Intraday)               *   $8.75
* = custom scheduled Alerts only
ALERT Number of included prints        0

Format    Types   Prints
     1    $0.00    $0.00
     2    $2.00    $2.00
     3    $2.00    $2.00
     4    $4.00    $4.00
     5    $4.00    $4.00
     6    $0.00    $0.00
     7    $4.00    $4.00
     8    $0.00    $0.00
     9    $4.00    $4.00
    12   $40.00   $40.00
    18    $3.00    $3.00
    19   $60.00   $60.00
KWIC95    $1.25       NA
KWIC96    $4.00       NA

REDIST/COPY Multiplier Table:

      Range      Multiplier
        1-2       1.00
       3-25       1.50
     26-100       3.00
    101-200       4.00
    201-500       6.00
   501-1000       8.00
 1001 or more    10.00
ARCHIVE Multiplier Table:

      Range      Multiplier
       1-25       1.50
     26-200       3.00
    201-500       6.00
   501-1000       8.00
 1001 or more    10.00
---------------------------------

A charge of $20.00 applies to each CSS (Chemical Structure Search)
whether searching in one database or across multiple databases.  The
standard output charges for each database apply to any documents
retrieved.